Novavax Inc (NASDAQ: NVAX)
$9.5900
-1.2300 ( -8.41% ) 5.1M
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Market Data
Open
$9.5900
Previous close
$10.8200
Volume
5.1M
Market cap
$1.57B
Day range
$9.4810 - $11.4000
52 week range
$3.5324 - $23.8599
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 80 | Nov 12, 2024 |
8-k | 8K-related | 13 | Nov 05, 2024 |
8-k | 8K-related | 15 | Oct 16, 2024 |
8-k | 8K-related | 13 | Oct 03, 2024 |
4 | Insider transactions | 1 | Aug 21, 2024 |
4 | Insider transactions | 1 | Aug 20, 2024 |
8-k | 8K-related | 4 | Aug 08, 2024 |
10-q | Quarterly Reports | 92 | Aug 08, 2024 |
4 | Insider transactions | 1 | Jun 25, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |